Technivie is a drug owned by Abbvie Inc. It is protected by 19 US drug patents filed in 2015. Out of these, 9 drug patents are active and 10 have expired. Technivie's patents have been open to challenges since 19 December, 2018. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 13, 2032. Details of Technivie's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US8691938 | Anti-viral compounds |
Apr, 2032
(7 years from now) | Active |
| US8420596 | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(6 years from now) | Active |
| US8642538 | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(4 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US8420596 (Pediatric) | Macrocyclic hepatitis C serine protease inhibitors |
Oct, 2031
(6 years from now) | Active |
| US8686026 | Solid compositions |
Jun, 2031
(6 years from now) | Active |
| US9044480 | Compositions and methods for treating HCV |
Apr, 2031
(6 years from now) | Active |
| US9006387 | Anti-viral compounds |
Jun, 2030
(5 years from now) | Active |
|
US8268349 (Pediatric) | Solid pharmaceutical dosage form |
Feb, 2025
(2 months from now) | Active |
|
US8399015 (Pediatric) | Solid pharmaceutical dosage form |
Feb, 2025
(2 months from now) | Active |
| US8399015 | Solid pharmaceutical dosage form |
Aug, 2024
(3 months ago) |
Expired
|
| US8268349 | Solid pharmaceutical dosage form |
Aug, 2024
(3 months ago) |
Expired
|
|
US7364752 (Pediatric) | Solid dispersion pharamaceutical formulations |
May, 2021
(3 years ago) |
Expired
|
| US7364752 | Solid dispersion pharamaceutical formulations |
Nov, 2020
(4 years ago) |
Expired
|
|
US7148359 (Pediatric) | Polymorph of a pharmaceutical |
Jan, 2020
(4 years ago) |
Expired
|
| US7148359 | Polymorph of a pharmaceutical |
Jul, 2019
(5 years ago) |
Expired
|
|
US6037157 (Pediatric) | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) |
Expired
|
|
US6703403 (Pediatric) | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) |
Expired
|
| US6703403 | Method for improving pharmacokinetics |
Jun, 2016
(8 years ago) |
Expired
|
| US6037157 | Method for improving pharmacokinetics |
Jun, 2016
(8 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Technivie's patents.
Latest Legal Activities on Technivie's Patents
Given below is the list of recent legal activities going on the following patents of Technivie.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Nov, 2022 | US9044480 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Sep, 2022 | US9006387 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Sep, 2021 | US8691938 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Sep, 2021 | US8686026 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 Jul, 2021 | US8642538 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 Sep, 2020 | US8420596 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Nov, 2018 | US9044480 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Sep, 2018 | US9006387 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Sep, 2017 | US8686026 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Sep, 2017 | US8691938 |
FDA has granted several exclusivities to Technivie. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Technivie, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Technivie.
Exclusivity Information
Technivie holds 3 exclusivities. All of its exclusivities have expired in 2019. Details of Technivie's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-743) | Jul 24, 2018 |
| New Product(NP) | Jul 24, 2018 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Several oppositions have been filed on Technivie's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Technivie's generic, the next section provides detailed information on ongoing and past EP oppositions related to Technivie patents.
Technivie's Oppositions Filed in EPO
Technivie has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 15, 2016, by Ter Meer Steinmeister & Partner Patentanwälte Mbb. This opposition was filed on patent number EP11727080A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP15176068A | Apr, 2019 | Aechter, Bernd | Revoked |
| EP11727080A | Apr, 2016 | KELTIE LLP | Patent maintained as amended |
| EP11727080A | Apr, 2016 | Ter Meer Steinmeister & Partner Patentanwälte mbB | Patent maintained as amended |
US patents provide insights into the exclusivity only within the United States, but Technivie is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Technivie's family patents as well as insights into ongoing legal events on those patents.
Technivie's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Technivie's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 13, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Technivie Generics:
There are no approved generic versions for Technivie as of now.
Alternative Brands for Technivie
Technivie which is used for treating Hepatitis C virus (HCV) infection., has several other brand drugs in the same treatment category and using the same active ingredient (Ombitasvir; Paritaprevir; Ritonavir). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||
|---|---|---|---|---|---|---|
| Abbvie |
| |||||
About Technivie
Technivie is a drug owned by Abbvie Inc. It is used for treating Hepatitis C virus (HCV) infection. Technivie uses Ombitasvir; Paritaprevir; Ritonavir as an active ingredient. Technivie was launched by Abbvie in 2015.
Approval Date:
Technivie was approved by FDA for market use on 24 July, 2015.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Technivie is 24 July, 2015, its NCE-1 date is estimated to be 19 December, 2018.
Active Ingredient:
Technivie uses Ombitasvir; Paritaprevir; Ritonavir as the active ingredient. Check out other Drugs and Companies using Ombitasvir; Paritaprevir; Ritonavir ingredient
Treatment:
Technivie is used for treating Hepatitis C virus (HCV) infection.
Dosage:
Technivie is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 12.5MG;75MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |